Glenn Moro Tells Stock-Sector how NovaBay's Eyelid and Eyelash Cleanser, Avenova, Solves Long-Standing Problems in Eyecare
NEW YORK, NY / ACCESSWIRE / March 26, 2015 / Stock-Sector.com, an online source of news about promising medical, technology and energy companies, today announced that it is releasing an interview with Glenn Moro, Vice President of Avenova Sales and Marketing at NovaBay Pharmaceuticals (NYSE MKT:NBY), an Emeryville, CA, biopharmaceutical company developing novel antimicrobial products.
The interview focused on NovaBay's new eye hygiene product, Avenova. Stock-Sector caught up with Moro at the recent BIO CEO & Investor Conference, where NovaBay was one of the most intriguing companies that attended.
As Moro explained in the interview, more than 30 million Americans suffer from chronic conditions, such as blepharitis and dry eye syndrome, caused by bacteria growing on eyelids and eyelashes. These conditions are often painful, resulting in a crusty build-up on the lids and red, inflamed or dry eyes.
Doctors typically try to remove the debris on eyelids with baby shampoo or fight the inflammation with antibiotics or steroids, said Moro. But those treatments can only be used for a few weeks at a time-and after treatment stops, the conditions return.
In contrast, Avenova is the first lid and lash hygiene product that can be used daily, for months or years at time without fear of side effects. As Moro described, Avenova contains Neutrox, a pure stable version of hypochlorous acid (HOCl), a naturally occurring substance produced by white blood cells to fight microbial invaders. Lab tests show that in solution Neutrox (pure HOCL) kills microorganisms, blocks inflammatory toxins and prevents biofilm without any mammalian cell toxicity.
Both patients and doctors report that daily use of Avenova has finally brought relief from these chronic conditions.
To market Avenova, Moro and NovaBay have created a dedicated sales force in major cities across the country. The market for the product is estimated to be $500 million per year, said Moro. Aveno's potential growth was a primary reason for NovaBay Pharmaceuticals being chosen as WallStreetCorner.com's "Stock Pick of 2015."
View the interview here: https://youtu.be/dDF5T1XYcY8
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements.
Actual results, performance or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions, (ii) performance of financial markets, including emerging markets, and including market volatility, liquidity and credit events (iii) the frequency and severity of insured loss events, including from natural catastrophes and including the development of loss expenses, (iv) mortality and morbidity levels and trends, (v) persistency levels, (vi) the extent of credit defaults, (vii) interest rate levels, (viii) currency exchange rates including the Euro/U.S. Dollar exchange rate, (ix) changing levels of competition, (x) changes in laws and regulations, (xi) changes in the policies of central banks and/or foreign governments, (xii) the impact of acquisitions, including related integration issues, (xiii) reorganization measures, and (xiv) general competitive factors, in each case on a local, regional, national and/or global basis.
SOURCE: Stock-Sector.com
